Literature DB >> 18463813

Ossicle and vossicle implant model systems.

Glenda J Pettway1, Laurie K McCauley.   

Abstract

Bone regeneration and repair is a goal of many skeletal therapies and numerous agents positively or negatively impact these processes. New therapeutic agents and effective model systems are continually sought to identify agents and characterize their mechanisms of action are in constant demand. In addition, investigations of tumor cell-bone interaction in the skeletal metastatic microenvironment require well-defined and readily orchestrated models. This chapter describes a novel ectopic ossicle model and a vossicle modification that can be used to provide focused and rapid feedback of bone growth and bone-cellular interactions. The ossicle model is a bone marrow stromal cell (BMSC)-based model and the vossicle model is a neonatal vertebral bone transplant model. These models offer opportunities to mix and compare mesenchymal (donor derived) and hematopoietic elements (host derived). Multiple implants can be placed in one mouse to facilitate various outcome analyses, such as histomorphometry, micro-CT, gene expression studies, and cell tracking using markers such as luciferase, in response to pharma cological or genetic manipulation. Implants can also be combined with other cell types, such as cancer cells to evaluate the bone-tumor microenvironment.

Entities:  

Mesh:

Year:  2008        PMID: 18463813     DOI: 10.1007/978-1-59745-104-8_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging.

Authors:  Blake Eason Hildreth; Michelle M Williams; Katarzyna A Dembek; Krista M Hernon; Thomas J Rosol; Ramiro E Toribio
Journal:  Transgenic Res       Date:  2015-08-14       Impact factor: 2.788

2.  Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.

Authors:  Xin Li; Jinhui Liao; Serk In Park; Amy J Koh; William D Sadler; Kenneth J Pienta; Thomas J Rosol; Laurie K McCauley
Journal:  Bone       Date:  2011-03-17       Impact factor: 4.398

3.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

4.  Effect of Alendronate on Bone Formation during Tooth Extraction Wound Healing.

Authors:  R Tanoue; K Koi; J Yamashita
Journal:  J Dent Res       Date:  2015-06-29       Impact factor: 6.116

5.  Tissue engineering a surrogate niche for metastatic cancer cells.

Authors:  F Philipp Seib; Janice E Berry; Yusuke Shiozawa; Russell S Taichman; David L Kaplan
Journal:  Biomaterials       Date:  2015-03-04       Impact factor: 12.479

6.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Lalit R Patel; Anne M Ziegler; Aaron M Havens; Younghun Jung; Jingcheng Wang; Stephanie Zalucha; Robert D Loberg; Kenneth J Pienta; Russell S Taichman
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

7.  Calcium Sensing Receptor Function Supports Osteoblast Survival and Acts as a Co-Factor in PTH Anabolic Actions in Bone.

Authors:  Saja A Al-Dujaili; Amy J Koh; Ming Dang; Xue Mi; Wenhan Chang; Peter X Ma; Laurie K McCauley
Journal:  J Cell Biochem       Date:  2016-02-19       Impact factor: 4.429

8.  Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche.

Authors:  Younghun Jung; Junhui Song; Yusuke Shiozawa; Jingcheng Wang; Zhuo Wang; Benjamin Williams; Aaron Havens; Abraham Schneider; Chunxi Ge; Renny T Franceschi; Laurie K McCauley; Paul H Krebsbach; Russell S Taichman
Journal:  Stem Cells       Date:  2008-05-22       Impact factor: 6.277

9.  An in vivo mouse model for human prostate cancer metastasis.

Authors:  Aaron M Havens; Elisabeth A Pedersen; Yusuke Shiozawa; Chi Ying; Younghun Jung; Yanxi Sun; Chris Neeley; Jincheng Wang; Rohit Mehra; Evan T Keller; Laurie K McCauley; Robert D Loberg; Kenneth J Pienta; Russell S Taichman
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

10.  A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.

Authors:  Rachel K Surowiec; Lauren F Battle; Ferrous S Ward; Stephen H Schlecht; Basma M Khoury; Christopher Robbins; Edward M Wojtys; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2019-10-31       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.